NCT04906876View on ClinicalTrials.gov

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2025

Conditions
SarcomaSoft Tissue SarcomaMetastatic SarcomaUndifferentiated Pleomorphic SarcomaMyxofibrosarcomaLeiomyosarcomaLiposarcomaAngiosarcomaSynovial SarcomaRhabdomyosarcomaSpindle Cell SarcomaHigh Grade SarcomaBone Sarcoma
Interventions
DRUG

Gemcitabine

Gemcitabine as a 90-minute IV infusion

DRUG

Docetaxel

Docetaxel as a 60-minute IV infusion

DRUG

9-ING-41

9-ING-41 as an IV infusion over 1-4 hours twice weekly

Trial Locations (2)

02903

Hasbro Children's Hospital, Providence

Lifespan Cancer Insitute, Providence

Sponsors

Lead Sponsor

Brown University

Collaborators (1)

Actuate Therapeutics Inc.
All Listed Sponsors
collaborator

Actuate Therapeutics Inc.

INDUSTRY

lead

Brown University

OTHER

NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | Biotech Hunter | Biotech Hunter